Detalhe da pesquisa
1.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665782
2.
Clinical Application of Multimodal Sentinel Lymph Node Mapping Method in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: An Interim Analysis.
Ann Surg Oncol
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38717546
3.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37387213
4.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825192
5.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166679
6.
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 22(4): 499-511, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676601
7.
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Breast Cancer Res
; 23(1): 8, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451345
8.
Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer.
Int J Cancer
; 2021 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33905134
9.
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Breast Cancer Res Treat
; 188(1): 77-89, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33728524
10.
Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Breast Cancer Res Treat
; 188(2): 449-458, 2021 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-33909203
11.
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Breast Cancer Res Treat
; 189(3): 665-676, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34553296
12.
Genome-wide association study of genetic variants related to anthracycline-induced cardiotoxicity in early breast cancer.
Cancer Sci
; 111(7): 2579-2587, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32378780
13.
Cumulative incidence of chemotherapy-induced cardiotoxicity during a 2-year follow-up period in breast cancer patients.
Breast Cancer Res Treat
; 182(2): 333-343, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468335
14.
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
Breast Cancer Res Treat
; 184(3): 743-753, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32860168
15.
A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy.
Invest New Drugs
; 38(3): 866-873, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728715
16.
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Int J Cancer
; 145(6): 1669-1678, 2019 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30720867
17.
A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients.
Br J Cancer
; 120(5): 475-480, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30745582
18.
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Br J Cancer
; 120(2): 172-182, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568294
19.
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
Br J Cancer
; 121(12): 985-990, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31690831
20.
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Breast Cancer Res Treat
; 178(2): 367-377, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31407230